Drugs giant AstraZeneca has admitted that the formulation patent protecting its Seroquel XR product was deemed invalid by the High Court in the UK.
The patent was challenged by Accord Healthcare, Intas Pharmaceuticals, Hexal AG and Sandoz, Teva UK, and Teva Pharmaceutical Industries.
Astra assured that this decision is limited only to the UK market and is not binding in other countries. The District Court in The Hague, Netherlands, already found the formulation patent to be valid. Decisions from trials in the US and Spain are pending.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
AstraZeneca said it is "disappointed" with the court's decision and added that the company remains committed to defending its intellectual property protecting Seroquel XR.
Shares were down 0.26% to 2,844.00p.
March 2024 NS&I Premium Bond winners – check now to see what you've won
If you’re a Premium Bond holder, you can check from today (4 March) for any winnings from NS&I’s March 2024 Premium Bond draw
By Vaishali Varu Published
UK tax year end: full list of HMRC 2023/24 tax codes and what they mean explained
With a new UK tax year now only weeks away, you may be wondering what your tax codes mean.
By Henry Sandercock Published